Skip to main content

People with Type 2 diabetes who took the antidiabetes drug glitazone to decrease blood glucose levels and preserve the pancreas’ ability to produce insulin also had a reduced risk of developing Parkinson’s disease. Over a 10-year period, those who took glitazone had a 35% lower risk of developing Parkinson’s disease. Parkinson’s disease is a neurodegenerative disorder that affects about 2% of people age 65 and older. The prevalence increases with age.

These findings were reported in “Glitazone Use Associated With Reduced Risk Of Parkinson's Disease” by Brage Brakedal, BA, M.D.; Irene Flønes, M . . .

Content Restricted

This article is reserved for members with an active Standard Membership. Please purchase a Standard Membership to view this resource.


Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!

Close

Support Request

Need help now?

Call our toll-free phone number 877-350-6463